外周血LncRNA-CRNDE表达对弥漫大B细胞淋巴瘤患者疗效判断和预后评估的价值  

Value of peripheral blood LncRNA-CRNDE expression in evaluation of therapeutic effect and prognosis of patients with diffuse large B-cell lymphoma

作　　者：辛雪 王丽[1] 杜以萍 XIN Xue;WANG Li;DU Yiping(Oncology and Hematology,Qingdao Eighth People′s Hospital,Qingdao 266042,China)

机构地区：[1]青岛市第八人民医院血液内科,山东青岛266042

出　　处：《山东医药》2021年第34期6-10,共5页Shandong Medical Journal

基　　金：山东省医药卫生科研项目(2017WS068)。

摘　　要：目的探讨外周血长链非编码RNA(LncRNA)-CRNDE表达对弥漫大B细胞淋巴瘤(DLBCL)患者疗效判断和预后评估的价值。方法选取179例DLBCL患者为DLBCL组,另选取同期64例体检健康者为对照组,qRT-PCR法测定外周血LncRNA-CRNDE表达。比较DLBCL组治疗前后外周血LncRNA-CRNDE表达,比较不同疗效DLBCL患者治疗前后外周血LncRNA-CRNDE表达。K-M法绘制DLBCL患者无进展生存率和总生存率曲线。多因素Cox回归分析DLBCL患者预后不良的影响因素。ROC曲线分析外周血LncRNA-CRNDE表达对DLBCL患者预后不良的评估价值。结果DLBCL组外周血LncRNA-CRNDE表达高于对照组(P<0.05)。治疗后DLBCL组外周血LncRNA-CRNDE表达低于治疗前(P<0.05)。有效组治疗前后外周血LncRNA-CRNDE表达低于无效组(P<0.05)。外周血LncRNA-CRNDE表达与DLBCL患者Ann Arbor分期和国际预后指数相关(P<0.05)。LncRNA-CRNDE≥3.133组5年无进展生存率和总生存率低于LncRNA-CRNDE<3.133组(P均<0.05)。Ann Arbor分期Ⅲ~Ⅳ期、国际预后指数3~5分、LncRNA-CRNDE≥3.133为DLBCL患者预后不良的独立风险因素(P均<0.05)。外周血LncRNA-CRNDE表达评估DLBCL患者预后不良的曲线下面积、灵敏度、特异度为0.815(95%CI:0.771~0.854)、80.45%、66.48%。结论DLBCL患者外周血LncRNA-CRNDE高表达,LncRNA-CRNDE高表达与DLBCL患者疗效较差和预后不良相关,可作为预后评估指标。Objective To investigate the value of peripheral blood long non-coding RNA(LncRNA)-colorectal neoplasia differentially expressed(CRNDE)expression in the evaluation of the efficacy and prognosis of patients with diffuse large B-cell lymphoma(DLBCL).Methods A total of 179 DLBCL patients were selected as the DLBCL group,64 healthy people during physical examination in the same period were selected as the control group,and the expression of LncRNA-CRNDE in peripheral blood was determined by qRT-PCR.We compared the expression of LncRNA-CRNDE in peripheral blood before and after treatment in the DLBCL group,and compared the expression of LncRNA-CRNDE in peripheral blood of DLBCL patients with different therapeutic effects before and after treatment.The K-M method was used to draw curves of progression-free survival and overall survival of DLBCL patients.Multivariate Cox regression was used to analyze the factors affecting the poor prognosis of DLBCL patients.The ROC curve was used to analyze the evaluation value of the expression of LncRNA-CRNDE in peripheral blood for the poor prognosis of DLBCL patients.ResultsThe expression of LncRNA-CRNDE in the peripheral blood of the DLBCL group was significantly higher than that of the control group(P<0.05).After treatment,the expression of LncRNA-CRNDE in the peripheral blood of DLBCL group was significantly lower than that before treatment(P<0.05).The expression levels of LncRNA-CRNDE in the peripheral blood before and after treatment in the effective group were significantly lower than those in the ineffective group(both P<0.05).The expression of LncRNA-CRNDE in the peripheral blood was related to Ann Arbor staging and international prognostic index of DLBCL patients(P<0.05).The 5-year progression-free survival rate and overall survival rate in the LncRNA-CRNDE≥3.133 group were significantly lower than those in the LncRNA-CRNDE<3.133 group(both P<0.05).Ann Arbor stagingⅢ-Ⅳ,international prognostic index 3-5,and LncRNA-CRNDE≥3.133 were independent risk factors for poor

关 键 词：弥漫大B细胞淋巴瘤 长链非编码RNA 结直肠肿瘤差异表达基因 

分 类 号：R733.1[医药卫生—肿瘤]